OTCMKTS:ARSSF

Assura (ARSSF) Stock Forecast, Price & News

$0.52

0.00 (0.00%)

(As of 09/22/2023 ET)

Compare

Today's Range: $0.52
▼
$0.52
50-Day Range: $0.52
▼
$0.66
52-Week Range: $0.52
▼
$0.74

Volume: N/A
Average Volume: 5,250 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $79.00

Profile Analyst Ratings Chart Competitors Headlines Short Interest

About Assura (OTCMKTS:ARSSF) Stock

Assura plc is a national healthcare premises specialist and UK REIT based in Warrington, UK - caring for more than 600 primary healthcare buildings, from which over six million patients are served. A constituent of the FTSE 250 and the EPRA indices, as at 31 March 2023, Assura's portfolio was valued at £2.7 billion. At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026. Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.

ARSSF Price History

30 days | 90 days | 365 days | Advanced Chart

ARSSF Stock News Headlines

September 21, 2023 | msn.com

Ruedi Bodenmann est «désolé»: Le directeur d'Assura s'excuse après des retards de remboursement

September 20, 2023 | msn.com

Le patron d'Assura présente ses excuses après des retards de remboursement

September 25, 2023 | UNKNOWN (Ad)

From Naval Flight Officer to CEO

First Female Founded, Publicly Traded, Space Company. Discover more

September 20, 2023 | americanbankingnews.com

Assura (OTCMKTS:ARSSF) Stock Price Down 11.6%

July 24, 2023 | lse.co.uk

Assura starts GBP11 million NHS ambulance hub development

July 6, 2023 | lse.co.uk

Assura notes strong growth pipeline, raises quarterly dividend

July 6, 2023 | marketwatch.com

Assura Completed Multiple Projects in 1Q

June 29, 2023 | lse.co.uk

Assura touts 100th development with completion of medical centre

September 25, 2023 | UNKNOWN (Ad)

From Naval Flight Officer to CEO

First Female Founded, Publicly Traded, Space Company. Discover more

June 5, 2023 | msn.com

Assura to relocate headquarters from Warrington to Greater Manchester

May 24, 2023 | msn.com

Peel Hunt Limited Reiterates Assura (LSE:AGR) Buy Recommendation

May 23, 2023 | lse.co.uk

Assura swings to annual loss after valuation movement; outlook hopeful

January 16, 2023 | lse.co.uk

Assura property portfolio and annualised rent roll fall in 2022

November 22, 2022 | msn.com

Assura profits plummet as boss blames interest rate rises and 'unhelpful' economic backdrop

November 22, 2022 | msn.com

Property developer Assura sees profits dive amid interest rates hikes

November 22, 2022 | marketwatch.com

Assura 1H Pretax Profit Fell; Warns About Lower Investment Activity Ahead

October 5, 2022 | msn.com

Assura reports 'good progress' and a strong portfolio

October 5, 2022 | marketwatch.com

Assura Portfolio Performed Well in 1H; Annualized Rent Rose

See More Headlines

Receive ARSSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assura and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: REIT—Healthcare Facilities
Sub-Industry: N/A
Sector: Real Estate
Current Symbol: OTCMKTS:ARSSF
CUSIP: N/A
CIK: N/A
Web: www.assuraplc.com
Phone: 44-1925-420660
Fax: N/A
Employees: 86
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $79.00
High Stock Price Forecast: $79.00
Low Stock Price Forecast: $79.00
Forecasted Upside/Downside: +15,073.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Jonathan Stewart Murphy ACA (Age 51)
MBA, CEO & Exec. Director
Comp: $1.09M

Ms. Jayne Marie Cottam (Age 49)
CFO & Exec. Director
Comp: $613.32k

Ms. Amanda Roddy
Sr. Investment Mang.

Ms. Joanne Cullen
Sr. Management Accountant

Mr. David Purcell
Investor Relations Director

Ms. Orla Ball
Head of Legal & Company Sec.

Ms. Debbie Chalcraft
Group Compliance Mang.

Ms. Francesca Harris
Marketing Mang.

Ms. Sarah Taylor
Chief People Officer

Mr. Robert James
Head of Devel.

Key Competitors

View All Competitors

ARSSF Stock - Frequently Asked Questions

Should I buy or sell Assura stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assura in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARSSF shares.
View ARSSF analyst ratings or view top-rated stocks.
What is Assura's stock price forecast for 2023?: 4 Wall Street analysts have issued 1 year price targets for Assura's stock. Their ARSSF share price forecasts range from $79.00 to $79.00. On average, they anticipate the company's share price to reach $79.00 in the next twelve months. This suggests a possible upside of 15,073.3% from the stock's current price.
View analysts price targets for ARSSF or view top-rated stocks among Wall Street analysts.
How have ARSSF shares performed in 2023?: Assura's stock was trading at $0.6283 on January 1st, 2023. Since then, ARSSF shares have decreased by 17.1% and is now trading at $0.5207.
View the best growth stocks for 2023 here.
Are investors shorting Assura?: Assura saw a decrease in short interest in the month of August. As of August 15th, there was short interest totaling 2,972,500 shares, a decrease of 36.7% from the July 31st total of 4,695,400 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
View Assura's Short Interest.

What is Assura's stock symbol?: Assura trades on the OTCMKTS under the ticker symbol "ARSSF."
How do I buy shares of Assura?: Shares of ARSSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Assura's stock price today?: One share of ARSSF stock can currently be purchased for approximately $0.52.
How can I contact Assura?: Assura's mailing address is The Brew House, Warrington, Cheshire WA4. The official website for the company is www.assuraplc.com. The company can be reached via phone at 44-1925-420660.

This page (OTCMKTS:ARSSF) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial